Oncotice (Bacillus Calmette-Guérin (Bcg), Tice)

Bacillus Calmette-Guérin, the active ingredient in Oncotice, is a live‑attenuated bacterial vaccine presented as a suspension for intravesical use. It is employed in the treatment of non‑muscle‑invasive bladder cancer, primarily in patients who have undergone transurethral resection of the tumour. GNH USA supplies Oncotice as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH USA supplies Oncotice as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Oncotice is a live‑attenuated bacterial therapy that focuses on the uro‑genital tract ​​​​  ​  ​  ​    ​     ​     ​                   ​           ​

- Non‑muscle‑invasive bladder cancer: reduces recurrence and progression after ​   ​  ​   ​   ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​ - Carcinoma‑in‑situ (CIS) of the bladder : provides  ​  ​  ​    g  g  - High risk patients : offers  ​   g  -  -  - 

The